Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bay 65-1942 hydrochloride is an inhibitor of ATP-competitive and selective IKKβ.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 789 | 5日内发货 | ||
5 mg | ¥ 1,410 | 5日内发货 | ||
25 mg | ¥ 5,920 | 6-8周 | ||
50 mg | ¥ 7,850 | 6-8周 | ||
100 mg | ¥ 12,500 | 6-8周 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,710 | 5日内发货 |
产品描述 | Bay 65-1942 hydrochloride is an inhibitor of ATP-competitive and selective IKKβ. |
体外活性 | Delivery of Bay 65-1942 prior to ischemia significantly decreases left ventricular infarct size compared with animals receiving vehicle. This ratio is significantly reduced by treatment with Bay 65-1942 at each time point (prior to ischemia 42.7±4.1%, at reperfusion 42.7±7.5%, 2 h of reperfusion 29.4±5.2%; each group P<0.05 vs. vehicle). Compared with sham animals, animals receiving vehicle have a significant increase in the infarct-to-area at risk (AAR) ratio (70.7±3.4 vs. 5.8±3.4%, P<0.05). Animals pretreated with Bay 65-1942 (n=3) have significantly attenuated CK-MB levels compared with those animals without treatment prior to IR (14,170 ±3,219 units, P<0.05 vs. vehicle)[1]. |
体内活性 | AZD6244 and BAY 65-1942 demonstrate synergistic inhibition of cell viability at the dose combination (5 μM AZD6244+10 μM BAY 65-1942), which correlates with IC75 (CI?=?0.48±0.01). AZD6244 and BAY 65-1942 treatment induces 2- and 1.3-fold caspase 3/7 activation, respectively, compared to the DMSO-treated cells. Treatment with a combination of AZD6244 plus BAY 65-1942 leads to a 3.2-fold increase in caspase 3/7 activity[2]. Inhibitors of MEK (AZD6244) and IKK (BAY 65-1942) are used at their IC50 concentrations, as determined by a 48 hour MTS assay, which achieve sufficient inhibition of kinase activity. MYL-R cells are treated for 24 hours with AZD6244 (5 μM), BAY 65-1942 (10 μM), or a combination of these inhibitors at the same concentrations. Synergism is also indicated at the IC50 (CI?=?0.56±0.09) and IC90 (CI?=?0.46±0.02) dose combinations reported by the software (CI values are the mean of three independent experiments, ± standard deviation). |
分子量 | 431.91 |
分子式 | C22H26ClN3O4 |
CAS No. | 600734-06-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (115.76 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3153 mL | 11.5765 mL | 23.153 mL | 57.8824 mL |
5 mM | 0.4631 mL | 2.3153 mL | 4.6306 mL | 11.5765 mL | |
10 mM | 0.2315 mL | 1.1576 mL | 2.3153 mL | 5.7882 mL | |
20 mM | 0.1158 mL | 0.5788 mL | 1.1576 mL | 2.8941 mL | |
50 mM | 0.0463 mL | 0.2315 mL | 0.4631 mL | 1.1576 mL | |
100 mM | 0.0232 mL | 0.1158 mL | 0.2315 mL | 0.5788 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Bay 65-1942 hydrochloride 600734-06-3 NF-Κb IκB/IKK Bay 651942 hydrochloride Bay 65 1942 hydrochloride Bay 65-1942 Hydrochloride Inhibitor inhibitor inhibit